1AD
ADALTA LIMITED
$0.0020
0.00%
Market cap
$6M
Turnover
—
Last price
$0.0020
Day change
0.00%
Announcements
22
Range, past year
Open 0.004 · Low 0.002 · Now 0.002 · High 0.008
Open 1AD in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
1AD momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
23/100
Wyckoff phase
Accumulation5d
Trend stage
Neutral
1 Day
+0.0%
1 Week
-33.3%
1 Month
-33.3%
1 Year
-33.3%
RSI
39
Avg daily range
39.3%
ADALTA LIMITED scores 23 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 5 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
What stands out
- Volume 1.8× 60-day avg
Points to watch
- 60d drawdown -50.0%
- High volatility (ATR 39.3%)
- Risk rating: Very High
- Composite downside risk elevated
1AD announcements
Recent price-sensitive releases.
- 2026-11-12 $1.4m additional RDTI refund Company Administration - Other
- 2026-10-26 Quarterly Appendix 4C and Activities Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-10-19 RDTI receipt, Advanced Overseas Finding Progress Report
- 2026-10-05 EW-001 JDC milestone approvals Progress Report
- 2026-10-01 China Representative Office opens Progress Report | Company Administration - Other
- 2026-09-23 US FDA grants EW-001 pre-IND meeting Progress Report
- 2026-09-18 Oribiotech deal validates AdAlta manufacturing strategy Progress Report
More Health Care stocks
Most traded in the same sector.